indicates that the methylation status of the ZMIZ1 gene predicts the outcome of a variety of solid cancers, including glioblastoma, astrocytoma, bladder cancer, and renal cell carcinoma, of which patients with hypomethylation of the ZMIZ1 gene exhibit worse survival compared to patients with hypermethylation of the gene (Mathios et al. 2019). The gene discussed is ZMIZ1; the disease is glioblastoma.